Efgartigimod Effective in Broad Subsets of Patients With gMG

Why It Matters

Efgartigimod’s broad efficacy could shift the gMG treatment paradigm toward earlier, antibody‑targeted therapy, expanding options for patients who previously relied on non‑specific immunosuppression.

Key Takeaways

• Efgartigimod achieved 63.8% responder rate vs 30.2% placebo.
• Efficacy observed regardless of prior immunosuppressive therapy or BMI.
• Both AChR‑positive and AChR‑negative patients showed clinical improvement.
• Adverse events similar to placebo, with 44.6% vs 33.3% incidence.
• Study limited by small subgroups and 26‑week duration.

Pulse Analysis

Generalized myasthenia gravis remains a therapeutic challenge, with most patients dependent on broad immunosuppressants that carry significant side‑effects. The disease is driven by pathogenic IgG autoantibodies targeting the acetylcholine receptor, making selective IgG‑reduction an attractive strategy. Efgartigimod, an FcRn antagonist, lowers circulating IgG levels without suppressing overall antibody production, positioning it as a precision‑medicine alternative to steroids and other conventional agents.

The ADAPT trial, expanded to include 167 adults with MG‑ADL scores of five or higher, confirmed the drug’s efficacy across diverse subpopulations. Responders—defined by meaningful improvements in MG‑ADL and Quantitative Myasthenia Gravis scores—were nearly twice as common in the efgartigimod arm, and the advantage persisted across age groups, genders, and BMI categories. Notably, patients who had previously received non‑steroidal immunosuppressants or were on stable acetylcholinesterase inhibitors still derived significant benefit, underscoring the drug’s versatility.

These findings have immediate market implications. By demonstrating consistent outcomes in both AChR‑positive and AChR‑negative cohorts, efgartigimod may become a first‑line option for a broader swath of the gMG population, potentially reducing reliance on long‑term steroids. While the trial’s limited size and 26‑week horizon temper definitive conclusions, the safety profile—comparable to placebo—strengthens the case for accelerated adoption. Stakeholders can anticipate heightened interest from payers and clinicians seeking targeted, tolerable therapies that improve quality of life while curbing treatment‑related burden.